PT Kalbe Farma Tbk
PTKFY
Other OTC8.69
USD
- -
- -
PT Kalbe Farma Tbk
PTKFY
(Other OTC)
Recent
price
8.69
P/E
ratio
- -
div
yld
- -
ROIC.AI
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- Similar Companies
- Business
- PT Kalbe Farma Tbk PT Kalbe Farma Tbk operates as Indonesia's largest integrated pharmaceutical and healthcare company, developing, manufacturing, marketing, and distributing a wide range of products across four primary divisions: prescription pharmaceuticals, consumer health, nutritionals, and distribution and logistics. The prescription pharmaceuticals division offers unbranded generics, branded generics, and licensed drugs targeting therapeutic areas such as oncology, neurology, cardiology, infectious diseases, diabetes, and cardiovascular conditions, including innovative biologics like Serplulimab (Zerpidio), Efepoetin Alfa (Efesa), Hemapo, Leucogen, Ezelin insulin, Rituxikal, Avamab, and Herzemab; the consumer health division provides over-the-counter drugs, health supplements, vitamins, minerals, energy drinks, and preventive products under strong brands like ExtraJoss, Mixagrip, Komix, Promag, Sakatonik, and new launches such as EJ SportGel, Entrostop, and Procold; the nutritionals division supplies products for all life stages, including infant formula, growing-up milk, adult supplements, and specialized nutrition for expectant and lactating mothers, children, teens, adults, seniors, and clinical needs; while the distribution and logistics division, managed through subsidiary PT Enseval Putera Megatrading Tbk, handles warehousing, transportation, and delivery of pharmaceuticals, consumer products, medical devices, and raw materials to over 200,000 outlets across Indonesia via 71 branches and three distribution centers, supported by digital platforms like EMOS and MOSTRANS. Headquartered in Jakarta and founded in 1966, the company serves domestic markets through an extensive network while exporting to approximately 40 countries in Southeast Asia, South Africa, and the Middle East, targeting hospitals, pharmacies, drug stores, retailers, and healthcare professionals with a focus on affordable, high-quality solutions compliant with national health insurance (JKN) programs and local content requirements. Recent developments include the establishment of a joint venture with Livzon Pharma Indonesia in July 2024 to manufacture pharmaceutical ingredients for export and domestic use, enhancing supply chain resilience and reducing US dollar dependency; a strategic partnership with Alliance Pharma Co., Ltd. (Thailand) signed in May 2024 to boost market penetration in Southeast Asia, particularly biologics in Thailand; commercialization of novel biologics Zerpidio and Efesa in 2024 with local FDA approvals and expansion into Southeast Asia, Middle East, and Australia; soft launching of radiopharmaceuticals facilities including a cyclotron; progress on local manufacturing of medical devices like dialyzers, mobile X-rays, endoscopy equipment, USG machines, CT-scans, surgical sutures, and TB kits to meet TKDN regulations; and receipt of the 2024 Proper Hijau award for sustainable development, alongside ongoing investments in R&D for drug delivery, biologics, cell therapy, vaccines, and affordable ready-to-drink nutritionals, with 1Q25 net sales reaching IDR 8,845 billion reflecting 5.8% growth.